within Pharmacolibrary.Drugs.ATC.L;

model L01XH05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.30666666666666664,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.378,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0035,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Entinostat is an oral class I selective histone deacetylase (HDAC) inhibitor that has been investigated primarily as an anticancer agent. It has been evaluated in clinical trials for the treatment of advanced solid tumors and hematological malignancies, often in combination with other anticancer agents. As of now, entinostat is not approved by major regulatory agencies for standard clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adult patients with advanced solid tumors in Phase I/II clinical trials following oral administration.</p><h4>References</h4><ol><li><p>Yang, X, et al., &amp; Hu, L (2014). Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 44(11) 1009–1013. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2014.919431&quot;>10.3109/00498254.2014.919431</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24831712/&quot;>https://pubmed.ncbi.nlm.nih.gov/24831712</a></p></li><li><p>Connolly, RM, et al., &amp; Piekarz, R (2017). Entinostat: a promising treatment option for patients with advanced breast cancer. <i>Future oncology (London, England)</i> 13(13) 1137–1148. DOI:<a href=&quot;https://doi.org/10.2217/fon-2016-0526&quot;>10.2217/fon-2016-0526</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28326839/&quot;>https://pubmed.ncbi.nlm.nih.gov/28326839</a></p></li><li><p>Masuda, N, et al., &amp; Iwata, H (2021). Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer. <i>BMC cancer</i> 21(1) 1269–None. DOI:<a href=&quot;https://doi.org/10.1186/s12885-021-08973-4&quot;>10.1186/s12885-021-08973-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34819039/&quot;>https://pubmed.ncbi.nlm.nih.gov/34819039</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XH05;
